Browsing Tag
Indian pharmaceutical manufacturing
2 posts
Natural Capsules (NSE: NATCAPSUQ) Q3 FY26 results signal operational recovery after regulatory shock, but fermentation execution risk still looms
Natural Capsules Limited’s Q3 FY26 results reveal regulatory recovery, tariff relief, and lingering API risks. Find out what this means for investors next.
Sigachi Industries (NSE: SIGACHI) secures SEIAA nod for Orvakal API project
Sigachi Industries gets SEIAA approval for its Orvakal API and specialty chemicals facility. Environmental clearance starts July 15. Read how this expansion reshapes growth.